Get started

Financials · XGN

Exagen Inc. (XGN) financials

For the twelve months ended Sep 30, 2026, Exagen Inc. reported $72.30M of revenue and -$18.17M of net income.

Revenue, TTM
$72.30M
Revenue growth, YoY
+13.7%
Net income, TTM
-$18.17M
Net margin
-25.1%
Free cash flow, TTM
-$13.03M
EPS, diluted, TTM
-$0.76
Cash
$28.09M
Total debt
$22.81M
P/S
1.76
Market cap
$127.4M
Annual revenue$66.58M
FY2018FY2025
Annual net income-$19.95M
FY2018FY2025
Annual free cash flow-$14.27M
FY2018FY2025

XGN revenue and earnings growth

XGN revenueQ3 2026$18.42M

Quarter YoY
+6.8%
QoQ
-7.6%
FY YoY
+19.7%
5Y CAGR
+9.7%

XGN revenue was $18.42M in fiscal Q3 2026 (ended Sep 30, 2026), up 6.8% from a year earlier and down 7.6% from the prior quarter. For the full fiscal 2025 it was $66.58M, up 19.7% from fiscal 2024. Compound annual growth was +9.7% over 5 years. It rose in 6 of the last 7 fiscal years. Fiscal 2025 is the highest of the 8 fiscal years on file.

XGN net incomeQ3 2026-$6.34M

XGN net income was -$6.34M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$7.09M a year earlier. For the full fiscal 2025 it was -$19.95M, compared with -$15.12M in fiscal 2024.

XGN EPSQ3 2026-$0.25

XGN diluted EPS was -$0.25 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.31 a year earlier. For the full fiscal 2025 it was -$0.93, compared with -$0.83 in fiscal 2024.

XGN free cash flowQ3 2026-$2.77M

XGN free cash flow was -$2.77M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $2.67M a year earlier. For the full fiscal 2025 it was -$14.27M, compared with -$13.79M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue$66.58M$55.64M$52.55M$45.56M$48.30M$41.98M$40.39M$32.44M
Cost of revenue$27.78M$22.53M$23.09M$24.21M$20.59M$16.56M$18.81M$15.38M
Gross profit$38.80M$33.11M$29.46M$21.35M$27.71M$25.42M$21.58M$17.06M
Research and development$6.25M$5.38M$4.87M$9.88M$7.24M$3.57M$2.18M$2.13M
Selling, general and admin$46.62M$41.37M$47.43M$52.02M$44.54M$37.03M$28.70M$19.68M
Operating income-$14.07M-$13.64M-$22.84M-$46.05M-$24.07M-$15.19M-$9.30M-$4.88M
Interest expense$4.32M$2.23M$2.33M$2.45M$2.63M$2.56M$3.49M$2.87M
Income tax$51.0K$12.0K$33.0K-$282.0K$175.0K-$79.0K$25.0K$58.0K
Net income-$19.95M-$15.12M-$23.69M-$47.39M-$26.85M-$16.69M-$12.04M-$8.01M
EPS, basic-$0.93-$0.83-$1.34-$2.77-$1.68-$1.32-$8.46-$293.34
EPS, diluted-$0.93-$0.83-$1.34-$2.77-$1.68-$1.32-$8.46-$293.34
Diluted shares21.6M18.2M17.7M17.1M16.0M12.6M3.6M63,005

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Cash and equivalents$32.22M$22.24M$36.69M$62.59M$99.54M$57.55M$72.18M$13.26M
Receivables$10.86M$7.83M$6.60M$6.10M$9.70M$8.91M$5.71M$5.95M
Current assets$48.89M$36.45M$47.84M$72.61M$112.73M$70.52M$81.25M$21.31M
Goodwill---$0$5.51M$5.51M$5.51M$5.51M
Total assets$58.02M$44.69M$56.94M$86.22M$123.44M$78.38M$88.31M$28.89M
Current liabilities$14.16M$13.51M$11.90M$9.62M$9.32M$8.77M$5.89M$8.95M
Short-term debt$643.0K$423.0K$264.0K$190.0K$0---
Long-term debt$22.26M$19.82M$19.23M$28.78M$27.48M$26.66M$25.85M$24.62M
Total debt$22.91M$20.25M$19.50M$28.97M$27.48M$26.66M$25.85M$24.62M
Total liabilities$40.57M$35.15M$34.25M$43.76M$38.51M$36.54M$32.65M$35.62M
Shareholders' equity$17.45M$9.54M$22.69M$42.46M$84.94M$41.84M$55.66M-$111.97M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Operating cash flow-$13.63M-$13.28M-$14.46M-$32.14M-$20.27M-$14.08M-$9.71M-$9.30M
Capital expenditures$641.0K$515.0K$828.0K$4.32M$2.37M$455.0K$403.0K$199.0K
Free cash flow-$14.27M-$13.79M-$15.29M-$36.46M-$22.64M-$14.54M-$10.11M-$9.50M
Investing cash flow-$626.0K-$515.0K-$804.0K-$4.32M-$2.42M-$455.0K-$103.0K-$199.0K
Financing cash flow$24.43M-$663.0K-$10.63M-$489.0K$64.68M-$97.0K$68.73M$11.42M
Stock-based compensation$2.16M$1.76M$3.62M$4.70M$4.73M$2.69M$572.0K$114.0K
Depreciation and amortization$2.10M$1.70M$2.20M$1.60M$900.0K$500.0K$600.0K$600.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue growth, YoY19.7%5.9%15.3%-5.7%15.1%3.9%24.5%-
Gross margin58.3%59.5%56.1%46.9%57.4%60.6%53.4%52.6%
Operating margin-21.1%-24.5%-43.5%-101.1%-49.8%-36.2%-23.0%-15.0%
Net margin-30.0%-27.2%-45.1%-104.0%-55.6%-39.8%-29.8%-24.7%
Free cash flow margin-21.4%-24.8%-29.1%-80.0%-46.9%-34.6%-25.0%-29.3%
Return on equity-114.3%-158.4%-104.4%-111.6%-31.6%-39.9%-21.6%-
Return on assets-34.4%-33.8%-41.6%-55.0%-21.8%-21.3%-13.6%-27.7%
Current ratio3.452.704.027.5512.108.0413.782.38
Debt to equity1.312.120.860.680.320.640.46-

Source: XBRL data Exagen Inc. files with the SEC, latest filing dated Nov 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

XGN peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
XGN$72.30M+13.7%-$18.17M-25.1%$127.4M
UNH$449.66B+3.3%$15.88B3.5%$363.00B
ELV$201.83B+3.6%$5.13B2.5%$92.83B
CI$286.32B+6.8%$5.99B2.1%$79.88B
HUM$154.19B+22.0%$1.25B0.8%$52.61B
NTRA$2.91B+37.4%-$164.71M-5.7%$45.24B
CNC$203.90B+9.7%$1.46B0.7%$34.75B
ILMN$4.54B+5.8%$895.00M19.7%$32.49B
LH$14.59B+6.0%$1.00B6.9%$30.12B

XGN FAQ

9 questions
  • What is XGN revenue?
    Exagen Inc. (XGN) reported $72.30M of revenue for the twelve months ended Sep 30, 2026. That is up 13.7% from the year before. Revenue for fiscal 2025 was $66.58M.
  • Is XGN profitable?
    No. Exagen Inc. reported a net loss of $18.17M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does XGN have?
    Exagen Inc. reported $28.09M in cash and cash equivalents and $22.81M of debt on its most recent balance sheet in SEC filings.
  • How fast is XGN revenue growing?
    Exagen Inc.'s revenue changed +19.7% in fiscal 2025, to $66.58M. Its compound annual growth rate was +9.7% over 5 years.
  • What is XGN gross margin?
    Exagen Inc.'s gross profit was $42.46M on $72.30M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 58.7%.
  • What is XGN free cash flow?
    Exagen Inc. generated -$13.03M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$12.02M less capital expenditures.
  • What is XGN earnings per share?
    Diluted earnings per share were -$0.76 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did XGN last report financial results?
    The latest statements here come from Exagen Inc.'s 10-Q filed on Nov 10, 2026, covering the period ended Sep 30, 2026.
  • Where does this XGN financial data come from?
    Quantisnow builds these statements from the structured XBRL data Exagen Inc. files with the SEC. It is provided for information only and is not investment advice.